Nicoś Marcin, Krawczyk Paweł, Crosetto Nicola, Milanowski Janusz
Department of Pneumonology, Oncology and Allergology, Medical University of Lublin, Lublin, Poland.
Science for Life Laboratory, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden.
Front Oncol. 2020 Dec 4;10:569202. doi: 10.3389/fonc.2020.569202. eCollection 2020.
Immune checkpoint inhibitors (ICIs) represent one of the most promising therapeutic approaches in metastatic non-small cell lung cancer (M-NSCLC). Unfortunately, approximately 50-75% of patients do not respond to this treatment modality. Intratumor heterogeneity (ITH) at the genetic and phenotypic level is considered as a major cause of anticancer therapy failure, including resistance to ICIs. Recent observations suggest that spatial heterogeneity in the composition and spatial organization of the tumor microenvironment plays a major role in the response of M-NSCLC patients to ICIs. In this mini review, we first present a brief overview of the use of ICIs in M-NSCLC. We then discuss the role of genetic and non-genetic ITH on the efficacy of ICIs in patients with M-NSCLC.
免疫检查点抑制剂（ICIs）是转移性非小细胞肺癌（M-NSCLC）中最有前景的治疗方法之一。不幸的是，约50-75%的患者对这种治疗方式无反应。遗传和表型水平的肿瘤内异质性（ITH）被认为是抗癌治疗失败的主要原因，包括对ICIs的耐药性。最近的观察表明，肿瘤微环境的组成和空间组织中的空间异质性在M-NSCLC患者对ICIs的反应中起主要作用。在本综述中，我们首先简要概述ICIs在M-NSCLC中的应用。然后我们讨论遗传和非遗传ITH对M-NSCLC患者ICIs疗效的作用。
